Chunghwa Chemical Synthesis & Biotech Co Ltd
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacturing, and sale of active pharmaceutical ingredients in Taiwan, the United States, India, Greece, Croatia, Japan, and internationally. The company offers antifungal, immunosuppressant, oncology, cardiovascular, peptide drug, immunomodulating agents, statin, muscle relaxant, ACE inhibitor with complete DM… Read more
Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.035x
Based on the latest financial reports, Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) has a cash flow conversion efficiency ratio of 0.035x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$112.62 Million) by net assets (NT$3.21 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Chunghwa Chemical Synthesis & Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Chunghwa Chemical Synthesis & Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Chunghwa Chemical Synthesis & Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chunghwa Chemical Synthesis & Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Petra Diamonds Limited
PINK:PDLMF
|
-0.150x |
|
SIFCO Industries Inc
NYSE MKT:SIF
|
0.209x |
|
Heungkuk F&M I
KO:000540
|
0.097x |
|
Wave Electronics Co. Ltd
KQ:095270
|
0.076x |
|
Hester Biosciences Limited
NSE:HESTERBIO
|
0.050x |
|
Sajodongaone Co Ltd
KO:008040
|
0.045x |
|
Suria Capital Holdings Bhd
KLSE:6521
|
-0.009x |
|
MIRA Pharmaceuticals, Inc. Common Stock
NASDAQ:MIRA
|
-0.145x |
Annual Cash Flow Conversion Efficiency for Chunghwa Chemical Synthesis & Biotech Co Ltd (2008–2024)
The table below shows the annual cash flow conversion efficiency of Chunghwa Chemical Synthesis & Biotech Co Ltd from 2008 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$3.36 Billion | NT$467.65 Million | 0.139x | +702.20% |
| 2023-12-31 | NT$3.35 Billion | NT$-77.50 Million | -0.023x | -110.07% |
| 2022-12-31 | NT$3.19 Billion | NT$733.78 Million | 0.230x | +203.46% |
| 2021-12-31 | NT$2.89 Billion | NT$219.18 Million | 0.076x | +36.88% |
| 2020-12-31 | NT$2.50 Billion | NT$138.24 Million | 0.055x | -58.42% |
| 2019-12-31 | NT$2.02 Billion | NT$268.13 Million | 0.133x | +12.49% |
| 2018-12-31 | NT$1.98 Billion | NT$234.66 Million | 0.118x | +35.20% |
| 2017-12-31 | NT$1.82 Billion | NT$159.34 Million | 0.087x | -40.70% |
| 2016-12-31 | NT$1.77 Billion | NT$261.31 Million | 0.148x | +245.00% |
| 2015-12-31 | NT$1.86 Billion | NT$79.70 Million | 0.043x | +199.40% |
| 2014-12-31 | NT$1.62 Billion | NT$23.08 Million | 0.014x | -83.17% |
| 2013-12-31 | NT$1.71 Billion | NT$145.24 Million | 0.085x | -47.02% |
| 2012-12-31 | NT$1.68 Billion | NT$268.46 Million | 0.160x | +85.46% |
| 2011-12-31 | NT$1.68 Billion | NT$144.84 Million | 0.086x | -47.25% |
| 2010-12-31 | NT$1.68 Billion | NT$275.61 Million | 0.164x | -57.67% |
| 2009-12-31 | NT$1.19 Billion | NT$462.07 Million | 0.387x | +329.84% |
| 2008-12-31 | NT$837.53 Million | NT$75.39 Million | 0.090x | -- |